[Clinical evaluation of ototoxicity associated with intravenous drip infusion of amikacin].
On the 53 patients with ENT (ears, nose, and throat) diseases, ototoxicity after intravenous drip infusion of amikacin (Biklin AMK) was studied. Each dose of AMK was 400 mg/day in adults and 4--8 mg/kg/day in children. From audiometric analysis, there were no patients with any hearing disturbances and subjective complaints concerning labyrinth injury. Also abnormal laboratory findings were not found in them. An intravenous drip infusion of AMK in adequate dosage would be beneficial to use against some infectious diseases of otorhinolaryngologic field.
D000293:Adolescent; D000328:Adult; D000583:Amikacin / Q000008:administration & dosage / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001424:Bacterial Infections / Q000188:drug therapy; D002648:Child; D004423:Ear / Q000187:drug effects*; D005260:Female; D006309:Hearing / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D007612:Kanamycin / Q000031:analogs & derivatives*; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy
D007612:Kanamycin; D000583:Amikacin